omeprazole

Also found in: Dictionary, Thesaurus, Wikipedia.

Related to omeprazole: ranitidine, Losec

omeprazole

[o-mep´ra-zōl]

a proton pump inhibitor, used in treatment of dyspepsia, gastroesophageal reflux disease, disorders of gastric hypersecretion, and peptic ulcer, including that associated with Helicobacter pylori infection; administered orally.

omeprazole

/omep·ra·zole/ (o-mep´ra-zōl) an inhibitor of gastric acid secretion used in the treatment of dyspepsia , gastroesophageal reflux disease, disorders of gastric hypersecretion, and peptic ulcer, including that associated with Helicobacter pylori infection.

omeprazole

(ō-mĕp′rə-zōl′)

A proton pump inhibitor drug, C₁₇H₁₉N₃O₃S, that suppresses gastric acid secretion and is used for the treatment of duodenal and gastric ulcers and gastroesophageal reflux disease.

omeprazole

Prilosec^® Therapeutics A proton pump inhibitor used to manage GERD; heartburn; erosive esophagitis; maintenance of healed erosive esophagitis; short-term management of active duodenal ulcer and active benign gastric ulcer, and for certain hypersecretory conditions; combined with clarithromycin to eradicate H pylori associated with duodenal ulcers. See GERD, Helicobacter pylori. Cf H2 blockers.

omeprazole

The first of the class of proton pump inhibitor drugs used to control the production of stomach acid and treat stomach and duodenal ulcers and especially the ZOLLINGER-ELLISON SYNDROME. OMEPRAZOLE can be effective in cases that have failed to respond to H-2 receptor blocker drugs such as RANITIDINE. The drug is long-acting and need only be taken once a day. A brand name is Losec.

omeprazole (ōmep´rəzōl´),

n brand name: Prilosec;
drug class: antisecretory compound;
action: suppresses gastric secretion by inhibiting hydrogen/potassium ATPase enzyme system in the gastric parietal cell;
uses: gastroesophageal reflux disease (GERD), severe erosive esophagitis, pathologic hypersecretory conditions (Zollinger-Ellison syndrome, mastocytosis, multiple endocrine adenomas).

omeprazole

a substituted benzimidazole that is a long-acting inhibitor of gastric ATPase; used in the treatment of gastric ulcers.

References in periodicals archive ?

AstraZeneca also supports the conclusion made by the FDA that the overall benefit/risk profiles of omeprazole and NEXIUM remain unchanged.

FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)

At 6 months, treatment success was reported for 31% on omeprazole, 21% on ranitidine, 13% on cisapride, and 14% on placebo, Dr.

Omeprazole gives long-term dyspepsia relief. (Canadian Study)

The patient was started on omeprazole and oral iron.

Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia

Mean time to first gastric pH >4 was significantly faster with PA32540 compared to the enteric-coated aspirin + enteric-coated omeprazole group (PA32540: 17 minutes; enteric-coated aspirin + enteric-coated omeprazole: 36 minutes; p=0.

PA32540 Provides Faster Gastric Acid Reduction Than Enteric-Coated Omeprazole (40 mg)

Subjects were excluded if they had: 1) use of any NSAID (including aspirin) within past 2 weeks or history of chronic NSAID use; 2) use of antacids, histamine (2) blocker within past 2 weeks, or PPI within past 30 days; 3) use of any corticosteroid within the past 60 days; 4) history of bleeding tendencies or warfarin use within the past 60 days; 5) history of previous bleeding ulcer; 6) consumption of three or more alcoholic beverages a day; 7) hypersensitivity or allergy to NSAIDs or omeprazole, or other contraindications to their use; 8) baseline abdominal pain, nausea, and/or cramping; or 9) the presence of one or more gastroduodenal mucosal breaks (erosions or ulcerations) at baseline endoscopy.

PPIs to prevent NSAID-induced GI ulceration

The study was funded by AstraZeneca, which makes omeprazole.

H. pylori Eradication

NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results today from a Phase 1 study comparing a dose-timing strategy of PA32540 and clopidogrel spaced 10 hours apart as compared to synchronous administration of enteric-coated (EC) omeprazole (40 mg), enteric-coated aspirin (81 mg) and clopidogrel (300 mg loading/75 mg daily).

Positive Results from POZEN Phase 1 Study ("Co-Rx") Presented At AHA

Important information about omeprazole and sodium bicarbonate capsules

Par Pharmaceutical Begins Shipment of Generic Zegerid

Lau, director of the endoscopy center at Prince of Wales Hospital in Hong Kong, presented the results of a double-blind, placebo-controlled trial of omeprazole in 369 patients with overt signs of upper GI bleeding who were scheduled for endoscopy.

GI bleeds healed by preemptive omeprazole

The man was prescribed 20mg/day of omeprazole, but no direct voice therapy.

A case of reflux laryngitis controlled with proton pump blockade alone

NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today positive top-line results of a Phase 1 study of PA32540, a novel coordinated-delivery tablet of enteric-coated (EC) aspirin (325 mg) and immediate-release (IR) omeprazole (40 mg).

POZEN Reports Superior Platelet Inhibition of PA32540 Regimen Over a Standard of Care Regimen in a Phase 1 Study ("Co-Rx")

CHICAGO -- Early high-dose omeprazole infusion speeds resolution of upper gastrointestinal bleeding and reduces the need for endoscopic treatment, according to preliminary results of a prospective trial from Hong Kong.